Ozempic and the Risk of nAMD A recent article in JAMA Ophthamology (June 2025) suggests that vascular changes triggered by GLP-1 activity may trigger or worsen nAMD in some patients, especially those who are older, diabetic, or already at risk for macular degeneration
x Na M.W

You may have relevant information if you: Purchased sublingual compounded tirzepatide tablets, tirzepatide chewing gum, or any oral tirzepatide product from The Wellness Company (twc.health) Received a compounded tirzepatide product in tablet, oral, sublingual, gum, liquid, or drops form through The Wellness Company or one of its partnered pharmacies Were told or led to believe that The Wellness Company oral tirzepatide product was equivalent to Mounjaro, Zepbound, or another FDA-approved GLP-1 medication Did not experience meaningful weight loss while taking the product Paid significant out-of-pocket costs for the product Experienced side effects or quality concerns with a The Wellness Company oral tirzepatide product If You Purchased Oral Tirzepatide Tablets, Tirzepatide Gum, or Another Oral Tirzepatide Product from The Wellness Company, We Want to Hear from You If you purchased sublingual tirzepatide tablets or tirzepatide gum from The Wellness Company, or received tirzepatide in oral form dispensed through one of The Wellness Companys partnered pharmacies, we would like to speak with you about your experience

Why Ongoing Care Matters Weight loss medications like semaglutide can be powerful tools, but they require medical oversight to ensure safety and success
What is the annual incidence of NAION in individuals over 50